



WILEY

Ask the Experts - Debunking Common Myths Associated with Flow Cytometry Compensation

Free webinar
Jan 20, 2021
12pm SGT

[Register here](#)



Comment on “Encephalopathy in patients with COVID-19: A review”

To The Editor,

I read with great interest the article by Garg et al¹ on “Encephalopathy in patients with COVID-19: A review.” The authors performed a review of published reports on coronavirus disease-2019 (COVID-19)-associated encephalitis and encephalopathy. They are to be congratulated for their timely, comprehensive, and insightful paper. Several aspects of cerebrospinal fluid analysis in patients with COVID-19 having neurological manifestations, however, need to be further discussed.

First, reliable cerebrospinal fluid (CSF) biomarkers to confirm the involvement of the central nervous system (CNS) in COVID-19 are still lacking. Previous reports, which mainly focused on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in CSF samples of patients with COVID-19 having neurological manifestations using reverse transcriptase-polymerase chain reaction (RT-PCR) tests, have reported inconsistent results. The majority of the studies have reported negative findings,^{2–6} whereas some have successfully detected SARS-CoV-2 RNA in CSF.^{7,8} These SARS-CoV-2 CSF PCR results should be interpreted with caution due to several reasons. The results were mainly based on case reports and case series, which may compromise on generalization. Also, the dynamics of SARS-CoV-2 in CSF are not fully understood and hence, no validated CSF assays are currently available. Furthermore, there are concerns about “false negative” SARS-CoV-2 PCR results, which have been observed to occur in up to 40% of throat sample tests.⁹ As such, a negative RT-PCR may not necessarily mean that SARS-CoV-2 is absent in the CSF. High-quality studies that are adequately powered to address these issues are urgently needed.

Second, whereas lack of identification of SARS-CoV-2 RNA in CSF may be indicative of the limitations of the currently available tests, it may also mean that the neurological manifestations could be mediated indirectly, through immune-related mechanisms. It is noteworthy that most of the above studies did not provide data on anti-SARS-CoV-2 antibodies within the CSF. Recently, several studies have successfully demonstrated the presence of these antibodies in the CSF of patients with COVID-19. Andriuta et al¹⁰ detected antibodies against S1 protein, S2 protein, and nucleoprotein of the SARS-CoV-2 in the CSF of two patients who presented with encephalopathy. Similarly, Benameur et al¹¹ demonstrated the presence of IgM for SARS-CoV-2 S1 and envelop proteins in three patients with COVID-19 having encephalitis. Interestingly, PCR analysis for viral RNA in the CSF of the patients in both studies yielded negative results. This observation is consistent with CSF findings from other viral encephalitis such as the Japanese encephalitis¹² and dengue

fever,^{13,14} where antibodies against these viruses were isolated in CSF samples in the absence of viral RNA. These preliminary findings suggest that anti-SARS-CoV-2 antibodies in CSF may be better indicators than viral RNA for CNS involvement in patients with COVID-19, and should be subject to further investigations to determine validated assays and their specificity and sensitivities.

ACKNOWLEDGMENT

The author received no financial support for the research, authorship, and/or publication of this article.

CONFLICT OF INTEREST

The author does not have any conflicts of interest with regard to this publication.

Isaac Cheruiyot BS 

School of Medicine, University of Nairobi, Nairobi, Kenya

Correspondence

Isaac Cheruiyot, BS, School of Medicine, University of Nairobi, Nairobi, Kenya.

Email: isaacbm@outlook.com

ORCID

Isaac Cheruiyot  <http://orcid.org/0000-0002-1211-8247>

REFERENCES

1. Garg RK, Paliwal VK, Gupta A. Encephalopathy in patients with COVID-19: a review [published online ahead of print June 19, 2020]. *J Med Virol*. 2020. <https://doi.org/10.1002/jmv.26207>
2. Al Saiegh F, Ghosh R, Leibold A, et al. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke [published online ahead of print April 30, 2020]. *J Neurol Neurosurg Psychiatry*. 2020. <https://doi.org/10.1136/jnnp-2020-323522>
3. Juliao Caamaño DS, Alonso Beato R. Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2. *J Clin Neurosci*. 2020;77:230-232. <https://doi.org/10.1016/j.jocn.2020.05.016>
4. Kilinc D, van de Pasch S, Doets AY, Jacobs BC, van Vliet J, Garssen MPJ. Guillain-Barré syndrome after SARS-CoV-2 infection [published online ahead of print June 13, 2020]. *Eur J Neurol*. 2020. <https://doi.org/10.1111/ene.14398>
5. Perchetti GA, Nalla AK, Huang M-L, et al. Validation of SARS-CoV-2 detection across multiple specimen types. *J Clin Virol*. 2020;128:104438. <https://doi.org/10.1016/j.jcv.2020.104438>

6. Sancho-Saldaña A, Lambea-Gil Á, Liesa JLC, et al. Guillain-Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection [published online ahead of print June 09, 2020]. *Clin Med Lond Engl*. 2020. <https://doi.org/10.7861/clinmed.2020-0213>
7. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis*. 2020; 94:55-58. <https://doi.org/10.1016/j.ijid.2020.03.062>
8. Zhou L, Zhang M, Wang J, Gao J. Sars-Cov-2: underestimated damage to nervous system [published online ahead of print March 24, 2020]. *Travel Med Infect Dis*. 2020:101642. <https://doi.org/10.1016/j.tmaid.2020.101642>
9. Yang J, Gong H, Chen X, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections [published online ahead of print February 17, 2020]. *medRxiv*. 2020. <https://doi.org/10.1101/2020.02.11.20021493>
10. Andriuta D, Roger P-A, Thibault W, et al. COVID-19 encephalopathy: detection of antibodies against SARS-CoV-2 in CSF [published online ahead of print June 11, 2020]. *J Neurol*. 2020:1-2. <https://doi.org/10.1007/s00415-020-09975-1>
11. Benameur K, Agarwal A, Auld SC, et al. Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease, Atlanta, Georgia, USA, 2020. *Emerg Infect Dis*. 2020;26(9):32487282. <https://doi.org/10.3201/eid2609.202122>
12. Dubot-Pèrès A, Sengvilaipaseuth O, Chanthongthip A, Newton PN, Lamballerie de X. How many patients with anti-JEV IgM in cerebrospinal fluid really have Japanese encephalitis? *Lancet Infect Dis*. 2015;15(12):1376-1377. [https://doi.org/10.1016/S1473-3099\(15\)00405-3](https://doi.org/10.1016/S1473-3099(15)00405-3)
13. Araújo F, Nogueira R, Araújo Mde S, et al. Dengue in patients with central nervous system manifestations, Brazil. *Emerg Infect Dis*. 2012; 18(4):677-679. <https://doi.org/10.3201/eid1804.111552>
14. Bastos MS, Martins V, Silva N, et al. Importance of cerebrospinal fluid investigation during dengue infection in Brazilian Amazonia Region. *Mem Inst Oswaldo Cruz*. 2018;114:e180450. <https://doi.org/10.1590/0074-02760180450>